The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report

Kirsi Santti, Annette Beule, Mikko Rönty, Hanna Ihalainen, Maija Tarkkanen, Carl Blomqvist

Research output: Contribution to journalLetterScientific

Original languageEnglish
JournalActa Oncologica
Number of pages4
ISSN0284-186X
DOIs
Publication statusE-pub ahead of print - 16 Mar 2019
MoE publication typeB1 Journal article

Fields of Science

  • CYCLIN D1 OVEREXPRESSION
  • EXPRESSION
  • THERAPY
  • BETA
  • PATHWAY
  • IMPACT
  • 3122 Cancers

Cite this

@article{1b31b10acb324c599552b216b5e60335,
title = "The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report",
keywords = "CYCLIN D1 OVEREXPRESSION, EXPRESSION, THERAPY, BETA, PATHWAY, IMPACT, 3122 Cancers",
author = "Kirsi Santti and Annette Beule and Mikko R{\"o}nty and Hanna Ihalainen and Maija Tarkkanen and Carl Blomqvist",
year = "2019",
month = "3",
day = "16",
doi = "10.1080/0284186X.2019.1588992",
language = "English",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "TAYLOR & FRANCIS LTD",

}

The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report. / Santti, Kirsi; Beule, Annette; Rönty, Mikko; Ihalainen, Hanna; Tarkkanen, Maija; Blomqvist, Carl.

In: Acta Oncologica, 16.03.2019.

Research output: Contribution to journalLetterScientific

TY - JOUR

T1 - The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report

AU - Santti, Kirsi

AU - Beule, Annette

AU - Rönty, Mikko

AU - Ihalainen, Hanna

AU - Tarkkanen, Maija

AU - Blomqvist, Carl

PY - 2019/3/16

Y1 - 2019/3/16

KW - CYCLIN D1 OVEREXPRESSION

KW - EXPRESSION

KW - THERAPY

KW - BETA

KW - PATHWAY

KW - IMPACT

KW - 3122 Cancers

U2 - 10.1080/0284186X.2019.1588992

DO - 10.1080/0284186X.2019.1588992

M3 - Letter

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

ER -